By using RT-qPCR and Western blotting analyses we found that SUFU and Wnt7a were upregulated in a dose-dependent manner in RL95-2 tumor xenograft tissues after NOMAC treatment, which is consistent with the results in vitro, Taken together, these results show that NOMAC inhibited the proliferation of type I endometrial cancer cell RL95-2 possibly associate with upregulating SUFU and Wnt7a in vivo and in vitro, but had no significant effect on the proliferation of type II cell line KLE and the expression of SUFU and Wnt7a. Here, WNT7A is linked to neoplasm.